The antiviral activity of 9-β-D-arabinofuranosyl adenine against vesicular stomatitis virus by Grant, John A.
University of Windsor 
Scholarship at UWindsor 
Electronic Theses and Dissertations Theses, Dissertations, and Major Papers 
1971 
The antiviral activity of 9-β-D-arabinofuranosyl adenine against 
vesicular stomatitis virus 
John A. Grant 
University of Windsor 
Follow this and additional works at: https://scholar.uwindsor.ca/etd 
Recommended Citation 
Grant, John A., "The antiviral activity of 9-β-D-arabinofuranosyl adenine against vesicular stomatitis virus" 
(1971). Electronic Theses and Dissertations. 8023. 
https://scholar.uwindsor.ca/etd/8023 
This online database contains the full-text of PhD dissertations and Masters’ theses of University of Windsor 
students from 1954 forward. These documents are made available for personal study and research purposes only, 
in accordance with the Canadian Copyright Act and the Creative Commons license—CC BY-NC-ND (Attribution, 
Non-Commercial, No Derivative Works). Under this license, works must always be attributed to the copyright holder 
(original author), cannot be used for any commercial purposes, and may not be altered. Any other use would 
require the permission of the copyright holder. Students may inquire about withdrawing their dissertation and/or 
thesis from this database. For additional inquiries, please contact the repository administrator via email 
(scholarship@uwindsor.ca) or by telephone at 519-253-3000ext. 3208. 
THE ANTIVIRAL ACTIVITY OF 
9_p-D-ARABIN0FURAN0SYL ADENINE 




Submitted to the Faculty of Graduate Studies through the 
Department of Biology in Partial Fulfillment 
of the Requirements for the Degree of 
Master of Science at the 
University of Windsor
WINDSOR, ONTARIO, CANADA 
1971
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
UMI Number: EC53073
INFORMATION TO USERS
The quality of this reproduction is dependent upon the quality of the copy 
submitted. Broken or indistinct print, colored or poor quality illustrations and 
photographs, print bleed-through, substandard margins, and improper 
alignment can adversely affect reproduction.
In the unlikely event that the author did not send a complete manuscript 
and there are missing pages, these will be noted. Also, if unauthorized 
copyright material had to be removed, a note will indicate the deletion.
®UMI
UMI Microform EC53073 
Copyright 2009 by ProQuest LLC.
All rights reserved. This microform edition is protected against 
unauthorized copying under Title 17, United States Code.
ProQuest LLC 
789 E. Eisenhower Parkway 
PO Box 1346 
Ann Arbor, Ml 48106-1346
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
APPROVED I 1
337261
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
ABSTRACT
Previously, Ara-A has been found to be an effective 
antiviral agent against DNA virus infections. In this 
study, antiviral activity was shown against an RNA 
virus, vesicular stomatitis virus. The inhibitory 
effect of Ara-A was found to occur early during virus 
replication. Cycloheximide, puromycin, and radioisotope 
incorporation experiments showed that Ara-A seems to 
stimulate protein synthesis while depressing RNA 
synthesis. The exact mode of action of Ara-A remains 
unclear, however some speculation concerning this 
problem is reported herein.
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INTRODUCTION
Although Lee et; al. (i9 6 0) first synthesized 
9-jJ-D-arabinofuranosyl adenine (Ara-A) with the 
objective of evaluating its effectiveness as an 
anticancer drug, subsequent studies have shown this 
drug to be a potentially useful antiviral. Privat de 
Garilhe and de Rudder (1964) found that Ara-A inhibited 
the production of infectious herpes simplex and vaccinia 
viruses in cell culture. The antiviral activity of 
Ara-A in vitro against vaccinia virus was confirmed 
by Freeman et al. (1 9 6 5). Studies by Sidwell and 
co-workers (1967,1 9 68) extended the range of antiviral 
activity of Ara-A in cell culture to include the 
cytomegaloviruses as well as experimental vaccinia 
virus infections in mice.
The expense of synthesis of Ara-A prevented 
extensive experimentation (Cohen, 1966) until this 
compound was isolated from a Streptomvces antibioticus 
(NRRL 3238) fermentation by Parke, Davis and Co. (1 9 6 8). 
Thereafter, in vivo experimentation for evaluating the 
therapeutic effect of Ara-A was possible. Therapeutic 
activity of Ara-A against experimental keratitis 
(Sidwell et al., 19 69) and encephalitis (Schardein
1
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and Sidwell, 1969) infections induced with herpes 
simplex virus in hamsters has been demonstrated.
Sloan et al. (1969) employed a wide range of 
dose levels and routes of administration of Ara-A 
in mice infected intracerebrally with herpes simplex and 
observed that Ara-A was highly therapeutic and only 
slightly toxic regardless of the route of administration 
of the drug.
Miller et al. (1 9 6 9) have carried out extensive 
screening of Ara-A against numerous DNA and RNA 
viruses in vitro. Their findings indicated the 
restriction of Ara-A inhibition to DNA virus infections. 
The only exception to their observations has been 
the controversial inhibition of Rous sarcoma virus 
specific foci. Freeman et al. (1965) reported no 
inhibition of Rous sarcoma virus, whereas Miller et. al.
(1 9 6 9) found Rous sarcoma foci to be inhibited by Ara-A. 
Inhibition of Rous sarcoma virus by Ara-A might be 
explained on the basis of the DNA requirement of this 
virus during replication (Bader, 1964,1966abj Temin, 
1964).
The present study was undertaken as a result of 
the finding that Ara-A inhibits the production of 
infectious vesicular stomatitis virus (an RNA virus)
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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grown in bovine kidney cell cultures.
Vesicular stomatitis virus (VSV) is a complex 
bullet-shaped virus about 68 x 175 nm in size 
(Howatson and Whitmore, 1962) which causes a serious 
disease in cattle and lacks a DNA requirement during 
its replicative cycle in vitro (Chamsey et al., 1963 
and Prevec et al., 1 9 6 3)* Bradish and Kirkham (19 66) 
have described the ultrastructure of VSV as consisting 
of four parts? a fringe of surface elements, a dense 
limiting envelope, an helical shell of capsomeres, and 
core material, with or without an axial hollow. In 
addition, they found that VSV generally exists in 
two states; bullet-shaped infectious particles (B) 
and truncated non-infectious (T) forms.
The nucleic acid core of VSV was found to be 
single stranded RNA having a molecular weight of 
3 x 10^ daltons (Brown et al., 1 9 6 7). Subsequent 
studies by Nakai and Howatson (19 68) showed that 
the intact virion core existed as a ribbon-like strand 
of a series of regular rod-like subunits having an 
overall helical configuration.
Recently, Stampfer et al. (1 9 69) demonstrated 
the complexity of VSV replication by isolating at 
least nine different species of virus-specific RNA
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
from infected cell cultures. Of these species# 
some were double stranded# some partially double 
stranded and some single stranded. When intact B 
and T particles were compared# it was found that 
B particles contained single stranded RNA sedimenting 
at *K)S while T particles carried single stranded RNA 
sedimenting at 19S. Furthermore, Baltimore et al.
(1970) have shown that VSV carries an RNA polymerase 
in the intact virion which is capable of synthesizing 
messenger RNA directly from the intact nucleocapsid 
as template without removal of protein (Baltimore, 
1970).
Evidence presented here suggests a unique mode 
of action of Ara-A against an RNA virus (VSV) which 
appears to lack a DNA requirement during replication 
in a cell line more closely related to the natural 
host of the virus than those commonly employed by 
other workers.




The MDBK bovine kidney cell line (Madin and 
Darby, 195$) used in these experiments was purchased 
from Baltimore Biological Laboratory, Baltimore,
Maryland, Monolayer cultures were grown and maintained 
in medium ELay-10 FCS as previously described (Sabina 
and Parker, 1963), For experimental purposes, Eagle's 
minimum essential medium (MEM) (Eagle, 1959) was 
employed. All culture media were sterilized by 
passage through 0.2u porosity Cox filter membranes.
VIRUS
The Indiana serotype of vesicular stomatitis 
virus (VSV) used in this study was supplied by Dr. N.A. 
Labzoffsky, Ontario Department of Health, Toronto, 
Ontario. Stock virus was prepared by infecting MDBK 
monolayers with an exposure multiplicity of ca. 2 
plaque forming units (p.f.u.) per cell. After adsorption 
for 1 hour at 37°C, medium ELay-10 FCS was added and 
cultures reincubated. At 2k hours postinfection, 
when the cytopathic effect was complete, all samples 
were subjected to three cycles of freezing and thawing
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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to release intracellular infectious virus. These 
suspensions were then centrifuged at 2000 r.p.m. for 
20 minutes in a Sorvall SS-3^ angle head rotor. The 
resulting infectious supernates were pooled and stored 
at -60°C. Titers of virus stocks ranged from 
2.9 x 10^ to 7 .5 x 10? p.f.u./ml.
INFECTION OF CELLS
MDBK monolayers grown in 1 oz. Brockway bottles 
were generally used after 48 hours incubation at 37°C. 
The medium was poured off and virus added at an 
infecting multiplicity of ca. 15 unless otherwise 
stated. Adsorption was allowed to proceed for 1 hour 
at 37°C with occasional agitation. Thereafter, 
residual virus innoculum was removed and the cultures 
rinsed with Hank's Balanced Salt Solution (HBSS) prior 
to the addition of medium MEM or MEM containing test 
compounds.
Control cell monolayers were handled in a similar 
fashion but received only MEM in place of virus 
innoculum. Unless otherwise indicated, all experiments 
were carried out once using duplicate cultures and held 
at -6o°C until assayed for infectivity or radioactivity.
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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VIRUS ASSAY
Infectivity was estimated by plaque formation 
in MDBK cell monolayers grown in 60-mm plastic tissue 
culture dishes (Falcon Plastics, Los Angeles, California). 
Replicate harvests of infectious virus from infected 
cultures were obtained in a similar fashion to that 
described under VIRUS. Log dilutions of the samples 
were made in medium MEM and 0.2 ml aliquots of 
appropriate dilutions were added to duplicate MDBK 
monolayers. After 1 hour at 37°C the cultures were 
overlaid with 5 nil of agar medium (Sabina and Munro,
1969). All dishes were then incubated at 3?°C in a 
water saturated atmosphere of 5$ C02 in air. The plaques 
were counted after approximately 2k hours.
ISOTOPES AND INHIBITORS
■^H-L-valine (specific activity, 1.5 Ci/mM), 
-^H-L-leucine (specific activity, 1 Ci/mM) and ^H-uridine 
(specific activity, 5*0 Ci/mM) were purchased from 
Amersham/Searle, Des Plaines, Illinois; cycloheximide 
(Acti-Dione) and puromycin dihydrochloride from 
Nutritional Biochemical Corp., Cleveland, Ohio; and 
actinomycin D from Sigma Chemical Co., St. Louis,
Missouri. The 9-j3-D-arabinofuranosyl adenine (micronized)
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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was made available by Dr. R. Brackett, Parke,
Davis and Co., Detroit, Michigan.
Stock solutions of all chemicals were made in 
MEM just prior to use, except actinomycin D and Ara-A 
which were initially solubilized in ethanol and 
dimethyl sulphoxide (DMSO), respectively.
RADIOISOTOPE INCORPORATION STUDIES
VSV-infected monolayers were prepared as described 
under INFECTION OF CELLS. Radioactive precursors were 
added to monolayers at various times after infection 
for 0.5 or 1 hour pulses. Incorporation of 
radioisotopes into cells was stopped by pouring off 
the medium and washing twice with ice-cold HBSS.
Cold 0 .5 N perchloric acid (PCA) was added to the 
washed monolayers for storage at -20°C until extraction 
procedures for RNA or protein were carried out. 
Uninfected cultures were treated similarly.
EXTRACTION AND DETERMINATION OF PROTEIN AND RNA
The extraction procedure for protein and RNA was 
carried out as follows. Frozen cell monolayers which 
had been exposed to radioactive precursors were thawed 
at room temperature and the acid-precipitated cells
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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scraped from the glass. Cell suspensions were 
transferred to centrifuge tubes and each culture 
bottle rinsed with cold 0.5 N PCA. Like suspensions 
were pooled and centrifuged. Each cell pellet was 
washed once with cold 0 .5 N PCA and dissolved in 
0 .5 N NaOH. Separate aliquots of this solution were 
taken for radioactivity and protein (Lowry et al., 1951) 
determinations.
For RNA determinations, the alkaline samples were 
incubated at 50°C for 20 minutes (Munro and Fleck,
1 9 6 6) and then reacidified to 0.5 N with respect to 
perchloric acid. After centrifugation, aliquants of 
the acid soluble fractions were removed for radioactivity 
and RNA (Merchant et al., i9 6 0) determinations.
RADIOACTIVITY ASSAY
Radioactivity was determined by the addition of 
samples to scintillation fluid (Warner and McClean,
1 9 6 8). Counts were obtained in a Nuclear Chicago 
liquid scintillation counter, using either model 
k6k3 or 6850. Specific activities are reported 
as counts per minute per milligram (c.p.m./mg) of 
RNA or protein.




In order to establish the time-course of 
VSV replication in MDBK cell monolayers, replicate 
infected cultures were removed at various times after 
infection and subsequently assayed for infectious virus. 
Figure 1 illustrates the rapid replication of VSV 
which reaches a maximum yield at about 16 hours 
postinfection. The latent phase is short and the 
duration of the logarithmic growth phase is about 6 
hours.
EFFECT OF ARA-A ON UNINFECTED MDBK CELLS
The effect of Ara-A on the survival of MDBK cells 
was determined by setting up a series of cultures with 
different concentrations of the drug in medium MEM. 
Following Zk hours of incubation at 37°C, cultures were 
checked for gross cytotoxicity at a magnification of 
400x using a Leitz inverted microscope. There was no 
evidence of cytotoxicity in cultures exposed to Ara-A 
in the range of 50 to 150 ug/ml when compared to 
untreated control cultures. However, in cultures 1 
exposed to 200 ug of Ara-A/ml, extensive rounding of
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Fig. 1. Multiplication of vesicular stomatitis 
virus in MDBK cells. Duplicate infected cultures 
were sampled at the indicated times. Infectious 
virus yields are expressed as plaque forming 
units (p.f.u.)/ml.
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cells and some free floating cells were observed.
EFFECT OF DMSO ON MDBK CELLS
Since DMSO has been shown to be deleterious to
certain cell lines and viruses (Chang and Simon, 1 9 68),
it was important to establish its effect on MDBK cells
and VSV replication. Replicate uninfected and VSV
infected MDBK monolayers were exposed to varying
concentrations of DMSO and allowed to incubate at 
o37 C until 2k hours postinfection. Similar cultures 
were observed in the absence of DMSO.
Microscopic examination of uninfected cultures 
with and without DMSO gave very similar appearances 
on the basis of gross morphology at a magnification 
of kOOx, The titers of infected cultures are shown 
in Table 1 . It appears that the highest concentration 
of DMSO tested (0,6%) did not result in any decrease 
in virus titer. The final concentration of DMSO used 
in the following experiments never exceeded 0,6%,
EFFECT OF ARA-A ON VSV INFECTIVITY
To evaluate the antiviral activity of Ara-A against 
VSV, the drug was applied to replicate infected cultures 
at levels of 50, 100 and 150 ug/ml. After 2k hours
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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Table 1.
The effect of different concentrations of DMSO on 
final infectious yields of VSV grown in MDBK cells.*
Concentration of DMSO (%) Viral Yields (p.f.u./ml)
0 2.2 x 106
0.2 2.0 x 106
0.6 3.0 x io6
* Indicated DMSO concentrations were added after 
virus adsorption and samples titrated at 24 hours 
postinfection.
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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of incubation at 37°C, infectious titers were determined 
and per cent plaque reduction values calculated.
It can be seen (Figure 2) that per cent plaque 
reduction rises almost geometrically as the concentration 
of Ara-A increases, indicating a typical dose-response 
relationship. All further studies in the presence 
of Ara-A were carried out at a final drug concentration 
of 150 ug/ml.
EFFECT OF MULTIPLICITY OF INFECTION ON VIRAL YIELDS 
AND ARA-A INHIBITION
Because multiplicity of infection has been shown 
to affect final yields of infectious virus (Stampfer 
et al., 1 9 69)* an experiment was carried out to 
establish the optimal multiplicity of infection in 
this test system.
Table 2 shows that maximal yields of VSV in the 
absence of Ara-A were obtained at a multiplicity of 
$.0. However, the inclusion of Ara-A resulted in a 
bicyclic pattern of inhibition. In order to evaluate 
the antiviral activity of Ara-A, it was pertinent to 
have the entire cell population infected, therefore, 
all subsequent experiments were begun with an infecting 
multiplicity of ca. 15*
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Fig. 2. The effect of different concentrations 
of Ara-A on final yields of infectious VSV.
Cultures were exposed to different concentrations of 
Ara-A as indicated after adsorption. Control cultures 
were incubated in MEM. Samples were titrated at Zk 
hours postinfection and per cent inhibition values 
calculated. Fig. 2 presents average per cent inhibition 
values from two experiments.
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Table 2.
The effect of multiplicity of infection on viral 
yields and Ara-A inhibition.*
Multiplicity of 
infection (p.f.u./cell)
Virus Yield (p.f .u../ml)
MEM MEM + Ara-A
0.01 5.7 x 10^ 1.0 X 105
0.1 4.0 x 106 6.0 X 105
1.0 5.2 x 106 3.8 X 106
3.4 4.4 x 106 1.7 X 106
5.0 8.? x 106 2.2 X 106
1 5 .0 8.7 x 106 1.0 X 106
* Duplicate cultures were exposed to the indicated 
infecting multiplicities. Ara-A (150 ug/ml), when 
present, was added after adsorption. Virus yields 
were determined at 24 hours postinfection.
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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MULTIPLICATION OF VSV IN THE PRESENCE OF ARA-A
To obtain information about the inhibitory effect 
of Ara-A upon VSV replication in MDBK cells, an 
experiment was performed similar to that described 
for the infectivity curve of VSV except that Ara-A 
was incorporated into medium MEM. The experimental 
results are shown in Figure 3«
Comparison of the infectivity curves of untreated 
cultures (Figure l) and Ara-A treated cultures (Figure 3) 
showed that Ara-A caused a rapid drop in virus yield 
beginning about 9 hours postinfection. With untreated 
cultures, the exponential rate of virus multiplication 
was extended until maximal steady levels were reached 
after 12 hours of infection.
ADDITION OF ARA-A TO INFECTED CELLS
Further definition of the period of Ara-A activity 
in MDBK infected cultures was studied by adding the 
drug at different intervals after infection for varying 
periods of time. Control infected cultures were allowed 
to incubate in medium MEM for the 24 hour test period. 
Infectious titers of the samples were determined and 
expressed as the per cent of the 2k hottr control 
culture (Figure k ).
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Pig. b, Effect on infectious yields of pulsing MDBK 
cells with Ara-A. Ara-A (150 ug/ral) was added to 
duplicate cultures for the indicated time periods.
Control infected cultures were incubated in MEM.
All samples were allowed to incubate for 2b hours.
When MEM containing Ara-A was removed, the cultures 
involved were washed twice with HBSS prior to the 
addition of MEM alone for reincubation.
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Fig. 3» Multiplication of VSV in the presence 
of Ara-A. Legend as for Fig, 1 except that Ara-A 
(150 ug/ml) was added to all cultures at the time of 
infection.
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The addition of Ara-A during the first 3 hours 
of infection resulted in about 70# inhibition whereas 
only a slight increase in inhibitory activity was 
evident when the drug was present from 6 to 2k hours 
postinfection. It is also clear that the presence of 
Ara-A during the first hour of infection did not 
effectively inhibit virus development. These effects 
suggest that Ara-A is most active early during viral 
replication but after the first hour of infection.
ADDITION OF PUROMYCIN AND ARA-A TO INFECTED CELLS
To determine whether Ara-A inhibition was dependent 
on protein synthesis, puromycin at a final concentration 
of 20 ug/ml was added to infected monolayers 
in combination with and without Ara-A. Virus-infected 
control cultures were incubated in medium MEM.
As shown in Figure 5» when puromycin was used 
for the first 3 hours after infection, the presence 
of puromycin and Ara-A showed less inhibition than 
did puromycin alone. During the 6 to 2k hour and 
0 to 2k hour periods, differences were relatively 
small. Apparently, Ara-A relieves puromycin inhibition 
rather than acting synergistically.
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Fig. 5» ^he effect on infectious yields of pulsing 
monolayers with puromycin (20 ug/ml) and puromycin 
(20 ug/ml) plus Ara-A (150 ug/ml) for the indicated 
time periods. Conditions were similar to those for 
Fig. 4, Solid bars indicate the effect of puromycin 
alone. Cross-hatched bars indicate the effect of 
puromycin plus Ara-A.
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ADDITION OF CYCLOHEXIMIDE AND ARA-A TO INFECTED CELLS 
To ascertain the influence of a different protein 
inhibitor in combination with Ara-A on VSV-infected 
cells, cycloheximide at a level of 20 ug/ml was tested 
as described in the preceding experiment. Since 
cycloheximide is reported to act by binding only to 
eukaryotic ribosomes (Brock, 1970), it was expected 
that only cellular protein synthesis would be affected 
in this experiment. The results are illustrated in 
Figure 6. The difference in inhibition induced by 
cycloheximide and puromycin was found to be only 
10 to 15%• Also, the addition of combined cycloheximide 
and Ara-A was considerably less inhibitory to virus 
production than cycloheximide alone.
INCORPORATION OF 3H-L-VALINE INTO INFECTED AND 
UNINFECTED CELLS WITH AND WITHOUT ARA-A
Since Ara-A had been shown to relieve inhibition 
of VSV replication by the protein inhibitors tested, 
it was of interest to discover whether Ara-A stimulated 
protein synthesis. Replicate cultures were pulsed 
for 1 hour at various times after infection with 
3H-L-valine as described under RADIOISOTOPE INCORPORATION 
STUDIES.
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Fig. 6. The effects of cycloheximide and 
cycloheximide plus Ara-A on VSV infectious yields. 
Legend as for Fig. 5 except cycloheximide (20 ug/ml) 
was substituted for puromycin.
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Figure 7A showed that Ara-A had a slight depressing 
effect on ^H-valine incorporation into uninfected 
cultures. With virus-infected cultures (Figure ?B), 
the rate of incorporation of ^H-valine into both 
Ara-A treated and untreated cultures was found to be 
gradually inhibited throughout the 10-hour test period. 
The magnitude of inhibition varied since cultures 
exposed to Ara-A up until 5 hours postinfection showed 
somewhat more radioactivity than untreated cultures 
at this time. Prolonged treatment with Ara-A caused 
similar inhibition of radioactivity incorporation 
compared to untreated cultures.
INCORPORATION OF 3H-L-LEUCINE IN THE PRESENCE OF 
ACTINOMYCIN D INTO INFECTED AND UNINFECTED CELLS 
WITH AND WITHOUT ARA-A
In order to preclude masking of viral events by 
normal cellular protein synthesis, actinomycin D at 
a final concentration of 3 ug/ml was added to all 
cultures. In these experiments, duplicate infected 
cultures were exposed to ^H-L-leucine for 0.5 hour 
pulses beginning at various times after infection.
When Ara-A was present, the drug was added at the time 
of infection.
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Pig. 7. ^H-L-valine incorporation into 
uninfected (A) and infected (B) cells in the presence 
and absence of Ara-A. General conditions for pulsing 
with ^H-L-valine uCi/culture), harvesting, 
extraction and counting procedures were described 
in MATERIALS AND METHODS. Ara-A (150 ug/ml) when 
used, was applied at the time of infection. Solid 
bars indicate the absence of Ara-A, cross-hatched 
bars its presence.
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The radioactivity incorporation profiles of 
uninfected cultures containing actinomycin D without 
and with Ara-A were essentially the same (Figure 8). 
When similarly treated infected cultures were compared, 
there was a greater rate of incorporation in Ara-A 
treated samples except during the 0,5 to 1 hour 
pulse (Figure 9)« Although infected cultures with 
Ara-A incorporated ^H-leucine at a greater rate, the 
pattern of incorporation was comparable to infected 
controls. Compared to the ^H-valine experiment, the 
general trend of incorporation of ^H-leucine after 
infection in the presence of actinomycin D was upward. 
This finding is consistent with the synthesis of viral 
directed proteins.
INCORPORATION OF 3H-URIDINE IN THE PRESENCE OF 
ACTINOMYCIN D INTO INFECTED AND UNINFECTED CELLS 
WITH AND WITHOUT ARA-A
It was necessary to observe the influence of 
Ara-A on viral RNA synthesis during VSV replication. 
Therefore, an experiment similar to the preceding one
3was carried out using H-uridine. When specific 
activities for uninfected cultures were obtained
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Fig. 8. ^H-L-leucine incorporation in the 
presence of actinomycin D into uninfected cultures 
without and with Ara-A. General conditions were as 
described for Fig. 7 except %-L-leucine (6 uCi/culture) 
was substituted for ^H-L-valine and actinomycin D 
(3 ug/ml) was present in all cultures.















Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Fig. 9. ^H-L-leucine incorporation in the 
presence of actinomycin D into infected cells without 
and with Ara-A. Legend as for Fig. 8 except infected 
cultures were used.
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Fig. 10. %-uridine incorporation in the 
presence of actinomycin D into uninfected cells 
with and without Ara-A. Legend as for Fig. 8 except 
-^H-uridine (3 uCi/culture) was used. Solid bars 
indicate the absence of Ara-A, cross-hatched bars 
its presence.
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(Figure 1 0), there was little change in the amount 
of incorporation of -^H-uridine throughout the 
experiment compared to infected cultures.
In infected cultures (Figure 11), the presence 
of Ara-A resulted in considerably lower amounts of 
incorporation during the first two pulses with little 
effect during the remaining pulses. The overall trend 
in the presence or absence of Ara-A showed a marked 
drop in the incorporation of radioisotope with time. 
Since actinomycin D had previously been shown not to 
affect VSV replication (Huang and Wagner, 1966 s Black 
and Brown, 19 68), these results were puzzling. The 
virus stock used in these experiments was checked 
for infectivity in order to exclude inactivation as 
a cause for such results. The stock virus suspension 
was found to be fully active. Shortly after the 
conclusion of these experiments, Yamazaki and Wagner 
(1970) reported similar findings with VSV in rabbit 
kidney cells. Even under such adverse conditions as 
described above, Ara-A still caused a reduced rate of 
incorporation of -^H-uridine compared to the infected 
control as early as the 0 .5 to 1 hour pulse.
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Fig. 11. ^H-uridine incorporation in the 
presence of actinomycin D into infected cells with 
and without Ara-A. Legend as for Fig. 8 except 
^H-uridine (3 uCi/culture) and infected cultures were 
used.
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INCORPORATION OF 3H-URIDINE INTO INFECTED AND UNINFECTED 
CELLS WITH AND WITHOUT ARA-A
Since actinomycin D was found unsuitable to 
study VSV RNA synthesis, the preceding experiment 
was duplicated in full without the addition of 
actinomycin D* These results are reported in Figures 
12 and 13. The incorporation rates for uninfected 
cultures (Figure 12) show little variation throughout 
the course of the experiment. Ara-A exhibited a slight 
depressing effect on incorporation in uninfected 
cultures. Infected cultures (Figure 13) without Ara-A 
demonstrated increased rates of incorporation of 
%-uridine over control values during pulses beginning 
at 0 .5, 3 .5, 5 .5 and ? hours after infection.
Comparison of Ara-A treated infected samples with 
uninfected controls showed the greatest increase in 
rate of incorporation during the first pulse. Specific 
activities for infected cultures with and without 
Ara-A (Figure 13) show generally lower rates of 
incorporation in the presence of Ara-A. In addition, 
the greatest differences were noted during the 0 .5 to 1 
and 5 .5  to 6 hour pulses,where values for cultures 
lacking Ara-A were considerably higher.
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Fig, 12, ^H-uridine incorporation into uninfected 
cells with and without Ara-A. Legend as for Fig. 7 
except ^H-uridine (3 uCi/culture) was substituted for 
•^H-L-valine.
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Fig. 13. 3H-uridine incorporation into infected 
cells with and without Ara-A. Legend as for Fig. 7 
except ^H-uridine (3 uCi/culture) and infected 
cultures were used.
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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Previously, studies of the antiviral activity of 
Ara-A have shown high therapeutic activity against 
DNA viruses but not against RNA viruses. This study 
reports the first incidence of Ara-A activity against 
an RNA virus (VSV) other than Rous sarcoma virus 
which has been shown to be dependent on DNA synthesis 
for replication (Bader, 1964-, 1966 abj Temin, 1964-).
Ara-A antiviral activity against VSV has been demonstrated 
to occur early during replication confirming the 
findings of Miller et al. (1969) in connection with 
DNA viruses.
Although Ara-A has been shown to be an effective 
antiviral agent (Miller et al., 19^9 j Sidwell et al..
1967, 1968, 1 969* Sloan et al., 1969) its exact mode 
of action remains unknown. On the basis of •'H-L-leucine 
incorporation in the presence of actinomycin D, evidence 
has been presented here indicating a lack of inhibition 
of viral protein synthesis by the drug. The relief 
by Ara-A of puromycin and cycloheximide inhibition 
of VSV infectivity may imply association of the drug 
with ribosomes and/or transfer RNA. This association, 
if it exists, does not seem to inhibit protein synthesis
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but in fact appears to stimulate the incorporation of
%-L-leucine in the presence of actinomycin D. This
3stimulation was apparently masked in the H-L-valine 
incorporation experiment which probably reflects the 
trend of cellular protein synthesis during VSV infection. 
The decrease in incorporation of %-L-valine as VSV 
infection progresses confirms recent findings by 
Wertz and Younger (1970).
Early viral RNA synthesis is partially inhibited 
by Ara-A as demonstrated by ^H-uridine incorporation 
but does not seem extensive enough to account for the 
inhibition of later viral RNA synthesis. Baltimore 
et al. (1970) have shown that early viral RNA synthesis 
in VSV-infected cells is directed by the intact 
infecting nucleocapsid and may be carried out by an 
RNA polymerase carried in the intact virion.
Furthermore, Baltimore (1970) has hypothesized that 
early viral RNA formation and replication of the 
viral genome are separate events. Therefore, the 
evidence presented here seems to indicate direct 
inhibition of the replication of the viral genome.
Lucas-Lenard and Cohen (1 9 66) have reported that 
the 5 ‘-diphosphate derivative of Ara-A (Ara-ADP) 
inhibits the action of the enzyme polynucleotide
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phosphorylase isolated from Esoherichia coli. This 
enzyme (Edmonds and Abrams, I960; Ventkataraman and 
Mahler, 1963) and one of its products, polyadenylic 
acid (Poly A) (Hadjivassiliou and Brawerman, 19 66), 
have been isolated from mammalian systems. Ara-A 
has also been shown to inhibit DNA synthesis in 
TA3 ascites cells (Brink and LePage, 19 66) and to 
inhibit DNA polymerase in mammalian cells (Furth and 
Cohen, 19 67).
Polynucleotide phosphorylase has been shown to 
be capable of synthesizing RNA (Grunberg-Manago'and 
Ochoa, 1955) and cellular RNA synthesis has been 
shown to be shut off rapidly after VSV infection 
(Huang and Wagner, 1965? Wertz and Younger, 1970). 
Therefore, one might speculate that this enzyme is 
similar to the RNA-dependent RNA polymerase carried 
in the VSV virion. Also, the comparatively little 
inhibition of early viral RNA formation may be a 
reflection of a protective effect due to complexing 
of the enzyme with the nucleocapsid.
As yet, there have been no reports dealing with 
radioisotope labelled Ara-A in viral infections.
In vitro studies of L cells by Cohen (19 6 6) failed 
to show incorporation of tritium-labelled Ara-A into
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DNA, RNA or nucleotides. York and LePage (196 6) 
found Ara-ATP inhibition of DNA polymerase in TA^ 
ascites cells to be non-competitive. These findings 
seem to indicate that Ara-A may inhibit VSV replication 
by affecting the enzyme responsible for the replication 
of the VSV genome although the drug does not seem to 
bind to the active site of similar enzymes.
In conclusion, although the exact mode of action 
of Ara-A against VSV remains to be determined, the 
drug does not appear to be a protein synthesis inhibitor 
but appears to block viral RNA synthesis in some manner.
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SUMMARY
Ara-A has been shown to be effective in inhibiting 
the replication of vesicular stomatitis virus (VSV) 
in MDBK cells as early as the first three hours of 
infection. Ara-A was shown to follow a typical dose- 
response relationship in this test system. When used 
in combination with the protein synthesis inhibitors 
puromycin and cycloheximide, Ara-A seems to relieve 
inhibition of infectivity rather than acting 
synergistically. Radioisotope incorporation studies 
showed that VSV infection shuts off protein synthesis 
in MDBK cells and that Ara-A did not affect this 
process. When incorporation of ^H-L-leucine in the 
presence of actinomycin D was studied, Ara-A was shown 
to stimulate incorporation. Incorporation experiments 
utilizing %-uridine demonstrated inhibition of viral 
RNA synthesis during the period of expected genome 
replication.
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